Environmental group urges action to reduce bacteria levels at local beaches
But every year, more and more, high bacteria levels are forcing officials to close beaches.
'Sometimes it's so hot you want to get in the water, but you don't want to because of how much bacteria is in the water, you don't want to get sick,' said Amy Villanueva of East Boston
Environmental advocates say the problem is getting more common.
'Forty-seven Massachusetts beaches had enough bacteria to put swimmers at risk on a quarter or more of days tested last year,' Devon Bell of Environment Massachusetts said.
At East Boston's Constitution Beach, environmental advocates released a study revealing that bacteria pollution is impacting beaches from the North Shore to the tip of Provincetown.
The most common culprit is storm water runoff from over development and sewage overflows.
And that leaves swimmers frustrated.
'When this is the only beach, you have access to, it's like you have to wait to get into the water, it doesn't feel like it's getting any better,' said Alejandra Andino of East Boston.
Environment Massachusetts says it will take billions of federal dollars to take the action needed to reduce coastal bacterial levels.
They are urging federal and state lawmakers to fight efforts to reduce spending.
'Everybody deserves a safe clean beach. We want to make sure Americans and people here have that opportunity as enshrined in the Clean Water Act,' said John Rumpler, the Clean Water Director for Environment Massachusetts.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The worst drinks for microplastic contamination revealed
Microplastics are all around us – in the air we breathe, in seas and rivers, they're found in the guts of sharks, and inside growing plants. They're also inside humans, too: in our blood, accumulating in our brains, and even in our testicles. So it is perhaps unsurprising to learn that one of the key means of entering the body is through the fluids we drink. Previous studies have established that microplastics are present in both tap water and bottled water, but new research has revealed that hot drinks may be an even bigger source of microplastics than was previously realised. A research team at the University of Birmingham tested 155 common soft drinks, including hot and cold drinks, for microplastics to get a picture of average human exposure through a realistic spectrum of daily drinks available in one country. The study, believed to be the first of its kind, found the highest concentrations of microplastics were in hot tea and hot coffee. The study also tested iced tea and coffee for microplastics, but found significantly less, suggesting the high temperatures and processes used for making hot drinks contribute to the levels of microplastics which end up in the product. The team assessed 31 different types of drinks in total from popular UK brands, all bought from supermarkets and coffee shops in 2024. These included hot and iced coffee, hot and iced tea, juices, energy drinks, and soft drinks. The samples were filtered, and then microplastic counts were determined through microscope imaging. Cold drinks were filtered immediately, while hot drinks were allowed to cool for 30 minutes before analysis. Hot tea in disposable cups contained the highest level of microplastics (MPs), averaging 22MPs per cup, compared to 14MPs per cup for glass cups. More expensive teabags leached the greatest amount of plastic, the study found, averaging 24 to 30MPs per cup. Similarly, the research team said that for hot coffee, their findings "strongly suggest that the disposable cup material is a primary source of [microplastics] in our hot coffee samples'. As not all samples were cup-sized, the team expressed their overall findings in microplastics per litre. Hot tea: 49 to 81 MPs per litre Hot coffee: 29 to 57 MPs per litre Iced tea: 24 to 38 MPs per litre Iced coffee: 31 to 43 MPs per litre Fruit juice: 19 to 41 MPs per litre Energy drinks: 14 to 36 MPs per litre Soft drinks: 13 to 21 MPs per litre The authors said their study "proves for the first time that assessment of exposure via drinking water only may substantially underestimate the risk" posed to humans by higher microplastics prevalence in other drinks. The same team published research in 2024, revealing the average microplastics concentration in tap water (24 to 56 MP per litre) was 'statistically indistinguishable" from that in bottled water (26 to 48 MP per litre). Professor Mohamed Abdallah from the University of Birmingham, who was one of the lead authors of the new research, told The Independent: "We noted that a lot of research in the microplastics sphere is focusing on drinking water – tap water, bottled water – and we've also released a paper from the UK on water. But we realised that people don't only drink water during their day. You drink tea, coffee, juices... "We found a ubiquitous presence of microplastics in all the cold and hot drinks we looked at. Which is pretty alarming, and from a scientific point of view suggests we should not only be looking at water, we should be more comprehensive in our research because other sources are substantial." He added: "We're consuming millions of teas and coffees every morning so it's something to definitely look at. There should definitely be legislative action from the government and also from international organisations to limit human exposure to microplastics … they're everywhere." The authors said the new research "serves as a critical step towards better understanding of the extent of MPs exposure under real-life scenarios, and advocates for more comprehensive studies for accurate risk assessment of MPs intake via dietary sources, to enable broader environmental and public health interventions".
Yahoo
3 hours ago
- Yahoo
Tainted fentanyl blamed for 87 hospital deaths in Argentina
At least 87 people have died in Argentina after being administered bacteria-infected fentanyl in hospitals, a judge investigating the deaths said Wednesday. Since May, a court has been trying to determine how many deaths are linked to batches of the drug contaminated with the bacteria Klebsiella pneumoniae and Ralstonia pickettii. The suspected toll has soared since then, with family members holding protests outside hospitals demanding justice. The probe arose from a complaint filed by Argentina's drug regulatory agency, Anmat, which had received a report from a hospital that discovered the tainted drug in its supply, an Anmat employee told AFP on condition of anonymity. The deaths have occurred in hospitals in the city and province of Buenos Aires, and in three other provinces, the judge leading the investigation, Ernesto Kreplak, told The Nation daily newspaper in an article published Wednesday. At least 24 people have been questioned and had their assets frozen by the court. They include Ariel Furfaro Garcia, owner of HLB Pharma and Ramallo Laboratories, which allegedly produced and sold the contaminated drug, The Nation reported. He denied the claims and blamed a former colleague for having planted the story in the media. "This was fabricated by the media. All the clinical histories show that the patients had other, more dangerous bacteria, people with serious problems," Furfaro Garcia told the daily newspaper Clarin. According to The Nation, at least five contaminated batches were distributed to eight hospitals and health centers in the country, although the investigation is looking at clinical histories from 200 hospitals. Two weeks ago, relatives of victims demonstrated outside the Italian Hospital in La Plata, 60 kilometers (37 miles) south of Buenos Aires, where the first deaths were reported, demanding "justice for the fentanyl victims." "The fentanyl caused his death in a matter of days," Alejandro Ayala, whose brother Leonel died at the age of 32, told AFP. Experts have warned that the death toll could rise as new medical records are reviewed and cases are confirmed in hospitals that to date had not reported any fentanyl-linked deaths. Argentina's Congress on Wednesday submitted 26 questions related to the case to the Executive branch of the government, but no deadline has been set for their response. mry/lm/ksb/sla
Yahoo
4 hours ago
- Yahoo
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketable securities of $147.6 million as of June 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ('Acrivon' or 'Acrivon Therapeutics') (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today reported financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. 'The strength of the clinical data across our two clinical assets speaks to the expanding capabilities of our AP3 platform to enable pathway-based drug design and optimized drug development by delivering actionable insights,' said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon. 'With ACR-368, we have seen deep and durable responses in patients with various types of aggressive endometrial cancer who had all progressed on prior chemotherapy and anti-PD1 therapy – a high unmet need population. Based on our clinical data, and the AP3-discovered insight that ultra low-dose gemcitabine sensitizes tumors to ACR-368 treatment, we believe there is an opportunity to further expand the patient population benefiting from ACR-368 by treating all-comer, biomarker-unselected 2nd line patients, who have all received prior chemotherapy and anti-PD-1, with ACR-368 and ultra low-dose gemcitabine. Our fully internally developed second clinical-stage asset, ACR-2316, which is being advanced in a Phase 1 trial, has demonstrated initial clinical activity during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer, signaling the broad potential of this agent.' Recent Highlights ACR-368: CHK1 and CHK2 Inhibitor Continued advancement of the ongoing registrational-intent, multicenter Phase 2b trial of ACR-368 in patients with recurrent high-grade endometrial cancer who have all received prior platinum-based chemotherapy and prior immune checkpoint inhibitor treatment regimens Initiated a third arm to the Phase 2b study without the need for a pre-treatment biopsy to evaluate ACR-368 with ultra low-dose gemcitabine (ULDG) as a tumor sensitizer in all-comer, biomarker-unselected 2nd line patients with endometrial cancer who have all received prior treatment with chemotherapy and anti-PD-1 ACR-2316: WEE1/PKMYT1 Inhibitor Continued enrolling patients in the Phase 1 monotherapy dose-escalation trial for certain high unmet need solid tumor types prioritized based on AP3-predicted sensitivity to ACR-2316 No dose-limiting toxicities observed in three cleared dose levels Evidence of drug target engagement observed as early as dose level 1 Initial clinical activity observed during dose escalation in several solid tumor types, including an ongoing confirmed partial response in endometrial cancer Generative Phosphoproteomics AP3 Platform At the AACR Annual Meeting in April 2025, presented Generative Phosphoproteomic AP3 analyses uncovering key molecular mechanisms by which ACR-2316 induces strong mitotic, pro-apoptotic tumor cell death believed to be critical for its potent, preclinical single-agent activity Anticipated Upcoming Milestones Provide update on registrational-intent trial and confirmatory trial design for ACR-368 in the second half of 2025 Report initial clinical data from the Phase 1 clinical study of ACR-2316 in the second half of 2025 Advance a new potential first-in-class cell cycle drug discovery program for an undisclosed target towards development candidate nomination in 2025 Second Quarter 2025 Financial Results Net loss for the quarter ended June 30, 2025 was $21.0 million compared to a net loss of $18.8 million for the same period in 2024. Research and development expenses were $16.2 million for the quarter ended June 30, 2025 compared to $15.0 million for the same period in 2024. The difference was primarily due to increased personnel to support the continued execution of the clinical trials for ACR-368 and ACR-2316, as well as preclinical drug discovery advancement. General and administrative expenses were $6.5 million for the quarter ended June 30, 2025, which is materially consistent with $6.4 million for the same period in 2024. As of June 30, 2025, the company had cash, cash equivalents and investments of $147.6 million, which is expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027. About Acrivon Therapeutics Acrivon is a clinical stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The Generative Phosphoproteomics AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome. These distinctive capabilities enable the company to go beyond the limitations of traditional drug discovery, as well as current AI-based target-centric drug discovery, and rapidly design highly differentiated compounds with desirable pathway effects through intracellular protein network analyses and advance these agents into the clinic for streamlined development. Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with endometrial cancer. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. In addition to ACR-368, Acrivon is also leveraging its proprietary Generative Phosphoproteomics AP3 platform for developing its co-crystallography-driven, internally discovered pipeline programs. These include ACR-2316, the company's second clinical stage asset, a novel, potent, selective WEE1/PKMYT1 inhibitor designed for superior single-agent activity through strong activation of not only CDK1 and CDK2, but also of PLK1 to drive pro-apoptotic cell death, as observed in preclinical studies against benchmark inhibitors. The Phase 1 trial of ACR-2316 is advancing with enrollment in the first three dose-escalation cohorts completed. Drug target engagement was observed at DL1 and 2 using the company's clinical mass-spectrometry-based AP3 profiling, with evidence of approximate dose proportionality based on plasma pharmacokinetic analyses, and initial clinical activity with tumor shrinkage observed at DL3. In addition, the company is advancing a preclinical program directed against an undisclosed cell cycle regulatory target. Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, preclinical and clinical results, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Forward-looking statements are based on Acrivon's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled 'Risk Factors' in our reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and Acrivon undertakes no duty to update such information except as required under applicable law. Investor and Media Contacts: Adam D. Levy, Ph.D., Alexandra Santos asantos@ Acrivon Therapeutics, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited, in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 16,182 $ 15,025 $ 31,596 $ 26,498 General and administrative 6,467 6,412 12,715 12,607 Total operating expenses 22,649 21,437 44,311 39,105 Loss from operations (22,649 ) (21,437 ) (44,311 ) (39,105 ) Other income (expense), net: Interest income 1,730 2,694 3,726 4,140 Other expense, net (87 ) (55 ) (101 ) (319 ) Total other income, net 1,643 2,639 3,625 3,821 Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Net loss per share - basic and diluted $ (0.55 ) $ (0.52 ) $ (1.06 ) $ (1.20 ) Weighted-average common stock outstanding - basic and diluted 38,461,619 36,132,616 38,406,339 29,361,710 Comprehensive loss: Net loss $ (21,006 ) $ (18,798 ) $ (40,686 ) $ (35,284 ) Other comprehensive income (loss): Unrealized (loss) gain on available-for-sale investments, net of tax (177 ) 51 (341 ) 64 Comprehensive loss $ (21,183 ) $ (18,747 ) $ (41,027 ) $ (35,220 ) Acrivon Therapeutics, Inc. Condensed Consolidated Balance Sheets (unaudited, in thousands) June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 41,895 $ 39,818 Investments 105,727 144,751 Other assets 10,961 12,019 Total assets $ 158,583 $ 196,588 Liabilities and Stockholders' Equity Liabilities $ 15,546 $ 19,802 Stockholders' Equity 143,037 176,786 Total Liabilities and Stockholders' Equity $ 158,583 $ 196,588 Sign in to access your portfolio
